288.29
전일 마감가:
$292.60
열려 있는:
$292.56
하루 거래량:
1.06M
Relative Volume:
0.84
시가총액:
$55.88B
수익:
$316.65B
순이익/손실:
$1.91B
주가수익비율:
29.66
EPS:
9.72
순현금흐름:
$1.14B
1주 성능:
-0.71%
1개월 성능:
-0.71%
6개월 성능:
+15.07%
1년 성능:
+21.26%
Cencora Inc Stock (COR) Company Profile
명칭
Cencora Inc
전화
610-727-7000
주소
1 WEST FIRST AVENUE, CONSHOHOCKEN
COR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
COR
Cencora Inc
|
288.23 | 56.29B | 316.65B | 1.91B | 1.14B | 9.72 |
![]()
MCK
Mckesson Corporation
|
679.39 | 83.49B | 377.60B | 3.35B | 5.67B | 25.08 |
![]()
CAH
Cardinal Health Inc
|
146.00 | 35.75B | 222.58B | 1.57B | 1.85B | 6.45 |
![]()
HSIC
Henry Schein Inc
|
68.47 | 8.15B | 12.50B | 314.00M | 421.00M | 2.44 |
![]()
AHG
Akso Health Group Adr
|
1.77 | 701.93M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2024-12-04 | 재개 | Mizuho | Outperform |
2024-09-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
2024-02-26 | 개시 | Leerink Partners | Outperform |
2024-01-03 | 개시 | Barclays | Overweight |
2023-12-14 | 개시 | Wells Fargo | Equal Weight |
2023-03-31 | 개시 | Citigroup | Buy |
2023-01-31 | 재개 | Evercore ISI | Outperform |
2022-10-11 | 업그레이드 | BofA Securities | Neutral → Buy |
2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
2022-07-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-06-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
2022-05-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
2022-04-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-04-01 | 재개 | Credit Suisse | Outperform |
2021-03-12 | 재개 | Evercore ISI | In-line |
2021-02-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
2021-02-02 | 업그레이드 | Cowen | Market Perform → Outperform |
2021-01-06 | 업그레이드 | BofA Securities | Underperform → Neutral |
2021-01-06 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2020-12-10 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
2020-12-03 | 개시 | Mizuho | Neutral |
2020-08-06 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2020-07-15 | 개시 | Barclays | Underweight |
2020-06-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-04-23 | 재개 | Credit Suisse | Outperform |
2020-04-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2020-04-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2020-04-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
2020-02-11 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
2020-02-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2019-09-12 | 개시 | Deutsche Bank | Hold |
2019-07-10 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
2019-04-11 | 개시 | Guggenheim | Buy |
2019-04-10 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
2019-04-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2019-02-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2019-01-17 | 개시 | UBS | Buy |
2018-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
2018-10-26 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2018-09-20 | 개시 | Berenberg | Buy |
2018-07-17 | 재개 | Stifel | Hold |
2018-04-09 | 개시 | MoffettNathanson | Buy |
2018-03-12 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-03-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2017-09-25 | 개시 | JP Morgan | Neutral |
2017-09-22 | 개시 | William Blair | Outperform |
모두보기
Cencora Inc 주식(COR)의 최신 뉴스
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Published on: 2025-08-21 02:56:19 - classian.co.kr
Cencora directors ink $111M deal related to opioid claims - MSN
Cencora Inc. Rebound Backed by Sentiment ShiftWeekly Market Report & Safe Investment Capital Preservation Plans - kangso.co.kr
Cencora Posts Modest 1.5 Gain as Volume Plunge Sends Stock to 405th Trading Rank Amid Sector Restructuring Focus - AInvest
What makes Cencora Inc. stock price move sharplyJuly 2025 Reactions & Verified Entry Point Signals - newsyoung.net
Cencora directors settle opioid claims for $111M - AInvest
Cencora directors ink $111M opioid deal (COR:NYSE) - Seeking Alpha
Cencora Shares Dip 0.70% as $320M Volume Ranks 332nd Amid Strategic Shifts and Sector Volatility - AInvest
$111.25M Del. Settlement Proposed For Cencora Opioid Suits - Law360
Cencora Directors Settle Opioid Claims for $111 Million - AInvest
Cencora Directors Reach $111 Million Deal on Opioid Claims - Bloomberg.com
Why Cencora (COR) is a Top Value Stock for the Long-Term - Yahoo Finance
Cencora’s 1.32% Rally Amid 295th-Ranked $350M Volume as Industry Navigates Regulatory Shifts and Profit Volatility - AInvest
Cencora Inc. Tests 50 Day MA After Sharp DeclineWeekly Stock Analysis & Stock Portfolio Risk Control - newsyoung.net
Will Cencora Inc. stock go up in YEARMarket Performance Report & Community Verified Watchlist Alerts - newsimpact.co.kr
Short Term Trend Reversal in Cencora Inc. PossibleJuly 2025 Catalysts & High Accuracy Buy Signal Tips - thegnnews.com
Cencora (COR) Stock Surpasses Market Gains with Strong PerformanceNews and Statistics - IndexBox
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
Cencora Stock: Analyst Estimates & Ratings - Yahoo Finance
Wells Fargo raises Cencora stock price target to $354 on strong U.S. Healthcare performance - Investing.com
Cencora price target raised to $354 from $337 at Wells Fargo - TipRanks
Stock Analysis | Cencora OutlookMixed Signals as Technicals and Analysts Diverge - AInvest
Cencora Plummets 0.53% Amid Regulatory Scrutiny Ranks 189th in $580M Trading Volume Despite Sector Resilience - AInvest
Investors Still Waiting For A Pull Back In Cencora, Inc. (NYSE:COR) - 富途牛牛
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap (NYSE:COR) - Seeking Alpha
Cencora (COR) Plummets 2.44% Amid Volatile Intraday Move: What’s Fueling the Selloff? - AInvest
Cencora Lifts Earnings Outlook After Strong Q3 Performance - MSN
Cencora & The Lash Group Settle Data Breach Litigation for $40 Million - The HIPAA Journal
Cencora (COR) Shares Jump 1.95% as Trading Volume Surges to $530M Ranking 184th in Market Activity - AInvest
3 Reasons Growth Investors Will Love Cencora (COR) - Yahoo Finance
RSI Suggests Rebound May Be Near in Cencora Inc.Top Gaining Picks With Entry Signals Identified - beatles.ru
Is It Smart To Buy Cencora, Inc. (NYSE:COR) Before It Goes Ex-Dividend? - simplywall.st
Why You Might Be Interested In Cencora, Inc. (NYSE:COR) For Its Upcoming Dividend - ca.finance.yahoo.com
Published on: 2025-08-10 00:34:30 - metal.it
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Cencora Rises 2.42% as Trading Volume Slumps to 313th Market Rank - AInvest
Cencora Q3: Growing Specialty Drug Distributions; Initiate At Buy (NYSE:COR) - Seeking Alpha
Research Alert: CFRA Raises View On Shares Of Cencora, Inc. To Buy From Hold - 富途牛牛
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results? - MSN
Cencora, Inc. Reports Strong Q3 2025 Financial Results - The Globe and Mail
Cencora Reports Strong Q3 2025 Financial Results - The Globe and Mail
Cencora: Fiscal Q3 Earnings Snapshot - New Haven Register
Cencora (COR) Reports Q3 Earnings Growth, Maintains US$0.55 Dividend - simplywall.st
Cencora’s Earnings Call: Strong Growth Amid Challenges - TipRanks
Cencora Earnings: Solid Results Illustrate Healthy Demand and Stable Outlook; Shares Fairly Valued - Morningstar
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook - AOL.com
Cencora Benefits From Strong GLP-1 Sales, Healthy Utilization Trends, and Growing Specialty Assets - Morningstar
Cencora, Inc. SEC 10-Q Report - TradingView
Cencora raises 2025 EPS guidance to $15.85–$16 and narrows outlook as specialty drives growth - MSN
Cencora weakness after earnings ‘overdone,’ says Leerink - TipRanks
Cencora Inc (COR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):